PHARMATRAIN News Contact

University of Basel - European Center of Pharmaceutical Medicine (ECPM)

Master of Advanced Studies in Medicines Development (MMD)

Practical Information

Commencing Date :
Any time
Language :
English
Location :
Basel Switzerland


Teaching Methodology :
Blended Learning


Scholarship Possibilities :
No

Course Contact

University of Basel - European Center of Pharmaceutical Medicine (ECPM)

University Accreditation : Yes

Centre of Excellence

Description

The European Center of Pharmaceutical Medicine (ECPM) designs and organizes the Master of Advanced Studies in Medicines Development program, together with partnering universities throughout Europe and other health care partner organizations. The program emphasizes integrated drug development, which is science-based, innovative, efficient and of high quality – leading to better and safer medical products for patients.

It is targeted at representatives from the pharmaceutical industry, service industry, academic and government decision- and policymakers who already have a good understanding of the basics of drug development and will benefit from a more in-depth, comprehensive and systematic immersion into modern medical product and device development, regulation and market introduction.

The program is structured in modules, which allows it to be completed next to working full- or part-time. Students can enroll in both the ECPM course and the master program.

In total, the Master of Advanced Studies requires a minimum of 60 ECTS.

30 ECTS (6 modules, triple exam) will be accredited by successfully completing the two-year ECPM Diploma Course - a well-established postgraduate education and training program - and acquiring the Diploma of Advanced Studies (DAS).

20 ECTS will be accredited for completing the master modules selected from the Continuing Professional Development (CPD) short courses list. These can be chosen by preference either from the ECPM CPD short course program, from other course providers or partner universities which offer training relevant to drug development sciences and the IMI PharmaTrain syllabus.

The remaining 10 ECTS will be accredited for writing and submitting a master thesis.

 

IMI Standards

  • A predefined set of teaching objectives, leading to defined learning outcomes
  • Assessment of the students' achievement in accordance with the agreed learning outcomes of the training offered
  • A system for collecting, assessing and addressing feedback from learners, teachers, technical / administrative staff and programme / course / module managers
  • Availability of appropriate and regularly reviewed reference material (e.g. published articles, links, book chapters, scripts, etc)
  • Defined and transparent admission criteria
  • Quality assurance of teaching staff
  • Regular review of the QA/QC process and demonstration that the training is further developed in light of this review
  • The facilities, infrastructure, leadership and competences available for the support of student learning
  • University accreditation OR a system for approving, monitoring and reviewing the training offered


Modules

Module Title

Type

Duration

Credits

CPD

Disease Biology-Based Pharmacology Core 3.0 ECTS No
Translational Science and Pharmacology Core 2.0 ECTS No
Drug Safety and Pharmacovigilance: E-Learning Core 1.0 ECTS
Essentials of Clinical Study Management Core 1.0 ECTS No
Pharmacoepidemiology Core 1.0 ECTS No
Basics in Health Economics: E-Learning Core Full Time 1.0 ECTS
Ethics and Regulation in Clinical Research Elective 1.0 ECTS No
Life Sciences Leadership and Business Strategies Core 3.0 ECTS No
Frontiers in Drug Development Elective Full Time 1.0 ECTS
Opening and Closing Presentations with POWER No
Scientific Medical Writing Elective 1.0 ECTS
BioBusiness Development Elective No